|Sarepta Therapeutics, Inc.|
215 First Street
United States - Map
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
|Sarepta Therapeutics, Inc.’s ISS Governance QuickScore as of Mar 1, 2014 is 8. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 6; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Christopher Nishan Garabedian ,
Chief Exec. Officer, Pres and Director
|Mr. Sandesh Mahatme ,
Chief Financial Officer, Chief Accounting Officer and Sr. VP
|Mr. David Tyronne Howton ,
Sr. VP, Gen. Counsel and Corp. Sec.
|Dr. Edward M. Kaye M.D., Ph.D.,
Chief Medical Officer and Sr. VP
|Mr. Michael A. Jacobsen ,
VP of Fin.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|